Response to apatinib by the number of metastatic organs in patients with advanced or metastatic gastric cancer: Subgroup analysis from a phase IV study (Ahead-G201)

Authors :: Haijun Zhong
Jianwei Yang
Mei Wang
Tienan Yi
Feng Ye
Zhong Xie
Lu Wen
Yuxian Bai
Jin Li
Tongfu Jia
Shukui Qin
Yi Ba
Xiaoyan Lin
Xiang-Yuan Wu
Yifu He
Yong Huang
Likun Liu
Guifang Zhang
Wenying Deng
Junsheng Wang
Source :: Journal of Clinical Oncology. 36:e16028-e16028
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e16028Background: Some studies have shown that number of metastatic sites is a significant prognostic factor in metastatic gastric cancer. In this subgroup analysis, data from a large phase IV tria...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Prognostic factor
business.industry
Subgroup analysis
Metastatic gastric cancer
chemistry.chemical_compound
chemistry
Internal medicine
medicine
Apatinib
In patient
business

Full Text Access

Tools